Ganetespib showed activity in KRAS-mutant NSCLC as monotherapy and in combinations
The investigational drug ganetespib, a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene. The drug was even more active ...
Jan 11, 2012
0
0